GlassScriptPhysician profile
Farhad G Nikoo
NPI 1740485101
$14,086.05
in general payments reported to CMS, 2019-2025
33 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,866 · 2022: $3,637 · 2023: $3,061 · 2024: $2,901 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,582.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,606.80 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,574.75 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,316.00 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $1,252.35 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,244.09 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $936.05 | 2021-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $808.79 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Lundbeck LLC | $733.86 | 2021-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $682.79 | 2022-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $635.08 | 2021-2025 | Fanapt, Hetlioz |
| Indivior INC. | $587.62 | 2021-2024 | Perseris, Sublocade |
| Sunovion Pharmaceuticals INC. | $423.78 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $365.26 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $308.92 | 2021-2025 | Trintellix |
| Corium, LLC | $274.35 | 2021-2024 | Azstarys |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $249.38 | 2021-2023 | Secuado, Xelstrym |
| Axsome Therapeutics, INC. | $197.56 | 2023-2024 | Auvelity |
| Bausch Health US, LLC | $153.45 | 2021-2024 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $150.21 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $124.88 | 2021 | |
| Livanova USA, INC. | $121.20 | 2021 | |
| Biogen, INC. | $63.51 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $49.06 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $44.33 | 2021 | |
| Vertical Pharmaceuticals, LLC | $38.14 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $24.56 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $24.52 | 2024 | Subvenite |
| Boston Scientific Corporation | $19.51 | 2023 | Infinion 16 |
| Tris Pharma INC | $17.82 | 2021 | |
| Merck Sharp & Dohme LLC | $17.70 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.07 | 2023 | Quviviq |
| Bioxcel Therapeutics, INC. | $15.86 | 2023 | Igalmi |
| Brainsway USA INC | $7.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Nikoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.